University of Groningen

Novel therapies in heart failureLiu, Licette Cécile Yang

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite fromit. Please check the document version below.

Document VersionPublisher's PDF, also known as Version of record

Publication date:2016

Link to publication in University of Groningen/UMCG research database

Citation for published version (APA):Liu, L. C. Y. (2016). Novel therapies in heart failure. [Groningen]: Rijksuniversiteit Groningen.

CopyrightOther than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of theauthor(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

Take-down policyIf you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediatelyand investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons thenumber of authors shown on this cover page is limited to 10 maximum.

Download date: 23-08-2020

Novel Therapies in Heart Failure

Licette C.Y. Liu

Licette Cécile Yang LiuNovel Therapies in Heart Failure

Copyright © 2016, Licette C.Y. LiuAll rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, without prior permission of the author.

Layout and printed by: Optima Grafische Communicatie, Rotterdam, the NetherlandsCover design: Liza Renee - Illustratie & Vormgeving, Groningen, the Netherlands.

Financial support for the publication of this thesis by the following institutes or com-panies is gratefully acknowledged:

University of Groningen, Graduate School of Medical Sciences, Pfizer B.V., Biotronic Nederland B.V., Servier Nederland Farma B.V., Amgen B.V., Daiichi Sankyo Nederland B.V., ChipSoft B.V., Bayer B.V.

ISBN: 978-94-6169-895-7E-pub ISBN: 978-94-6169-898-8

Novel Therapies in Heart Failure

Proefschrift

ter verkrijging van de graad van doctor aan deRijksuniversiteit Groningen

op gezag van derector magnificus prof. dr. E. Sterken

en volgens besluit van het College voor Promoties.

De openbare verdediging zal plaatsvinden op

woensdag 29 juni 2016 om 14.30 uur

door

Licette Cécile Yang Liu

geboren op 25 februari 1988te Hoogezand-Sappemeer

PromotorProf. dr. A.A. Voors

CopromotorDr. P. van der Meer

BeoordelingscommissieProf. dr. W.H. van GilstProf. dr. P.A. de GraeffProf. dr. M. Metra

Paranimfen drs. A. Fluitman drs. M.A. de Vries

Financial support by the Dutch Heart Foundation for the publication of this thesis is gratefully acknowledged.

To begin, beginWilliam Wordsworth (1770-1850)

TaBle oF CoNTeNTs

Introduction 13

Part I: Precision Medicine in Heart Failure

Chapter 1 A Novel Approach to Drug Development in Heart Failure: Towards Personalized Medicine

33

Chapter 2 Effects of Serelaxin in Acute Heart Failure Patients with Renal Impairment: Results from RELAX-AHF

51

Chapter 3 Identifying Subpopulations with Distinct Response to Treatment Using Plasma Biomarkers in Acute Heart Failure: Results from the PROTECT trial

71

Part II: Novel Drugs for the Treatment of Heart Failure with Preserved ejection Fraction

Chapter 4 Renal Effects of the Angiotensin Receptor Neprilysin Inhibitor LCZ696 in Patients with Heart Failure and Preserved Ejection Fraction

103

Chapter 5 Effects of Sildenafil on Invasive Hemodynamics and Exercise Capacity in Heart Failure Patients with Preserved Ejection Fraction and Pulmonary Hypertension: A Randomized Controlled Trial

123

Chapter 6 Effects of Sildenafil on Cardiac Structure and Function, Cardiopulmonary Exercise Testing and Health-Related Quality-of-Life Measures in Heart Failure Patients with Preserved Ejection Fraction and Pulmonary Hypertension

153

Part III: Drug evaluations of Novel Drugs for the Treatment of Heart Failure with Reduced ejection Fraction

Chapter 7 Finerenone: Third Generation Mineralocorticoid Receptor Antagonist for the Treatment of Heart Failure and Diabetic Kidney Disease

179

Chapter 8 Omecamtiv Mecarbil: a Novel Cardiac Myosin Activator for the Treatment of Heart Failure

203

General Discussion and Future Directions 225

Nederlandse Samenvatting 245

Dankwoord 255

Curriculum Vitae 261

List of Publications 263